Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Provided By GlobeNewswire
Last update: Jul 10, 2024
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody
Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors
Read more at globenewswire.com0.834
-0.01 (-1.08%)
Find more stocks in the Stock Screener
CNTX Latest News and Analysis
17 days ago - ChartmillUnusual volume stocks in Friday's sessionLet's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.
18 days ago - ChartmillThese stocks that are showing activity before the opening bell on Thursday.The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
